It has been shown that it is also dependent on the release of amphiregulins, HB-EGF and TGF-α, and the activations of EGFR/ErbB1 receptors on prostate cancer cells [52] and EGFR/ErbB1 and ErbB2 on breast cancer cells [7]. Here, EGFR is linked to breast carcinoma.